In order for ClinGen to maintain up-to-date gene-disease clinical validity classifications for use by clinicians and clinical laboratories, an appropriate timeline for reevaluating curated gene-disease associations will need to be determined. To provide guidance on how often a gene-disease association should be recurated, a retrospective analysis of 30 gene curations was performed. Curations were simulated at one-year intervals starting with the year of the first publication to assert disease-causing variants in the gene to observe trends in the classification over time, as well as factors that influenced changes in classification. On average, gene-disease associations spent the least amount of time in the "Moderate" classification before progressing to "Strong" or "Definitive." In contrast, gene-disease associations that spent five or more years in the "Limited" classification were most likely to remain "Limited" or become "Disputed/Refuted." Large population datasets contributed to the reclassification of several gene-disease associations from "Limited" to "Disputed/Refuted." Finally, recent advancements in sequencing technology correlated with an increase in the quantity of case-level evidence that was curated per paper. This study provided a number of key points to consider when determining how often to recurate a gene-disease association.
INTRODUCTION
The objective of the NIH-funded Clinical Genome Resource (ClinGen) is to build a central resource that defines the clinical relevance of genes and variants within specific disease entities for use in precision medicine and research. In order to facilitate this effort, the ClinGen Gene Curation Working Group developed a framework for curators to semi-quantitatively define the clinical validity of a gene-disease association (Strande et al., 2017) . This process involves the curation and systematic evaluation of peer-reviewed publicly available evidence to assign the strength of a gene-disease association into one of the following clinical validity classifications: Definitive, Strong, Moderate, Limited, No Reported Evidence, or Conflicting Evidence Reported.
As a resource for use by clinicians and clinical laboratories, it is important for the gene curation activities of ClinGen to reflect upto-date information for gene-disease associations. Thus, the need for reassessment of clinical validity classifications will be crucial, as additional information and evidence is published in the literature. This study examines how the clinical validity classification of a number of genes has changed over time and the factors that influenced those changes. By identifying those variables and trends in the clinical validity classifications over time, we can provide guidance for reevaluating curated gene-disease associations.
METHODS
A retrospective analysis of clinical validity classifications was performed on 22 gene-disease associations that were previously assigned a clinical validity classification using the ClinGen framework (Strande et al., 2017) (Table 1) . In order to identify information about the gene-disease association as it accumulated, PubMed searches were performed, limited to one-year intervals beginning with the first publication to assert disease-causing variants in a gene. 
Expert reviewed classification (points) Notes

KLHL24
Epidermolysis bullosa simplex (AD)
ORPHA N/A OMIM #617294
1:30,000-1:50,000 (Pfender & Bruckner, 1998) 2016 (1) (Lin et al.) Strong c (12 GE, 4 EE)
EXPH5, KRT5, KRT14, TGM5
account for ∼81% of cases (Pfender & Bruckner, 1998) .
SERPINB8
Exfoliative ichthyosis (AR)
ORPHA 289586 OMIM #617115
N/A 2016 (1) (Pigors et al.) Limited c (1.75 GE, 1 EE)
ATF6
Achromatopsia (AR) ORPHA 49382 OMIM #616517
< 1:30,000 (Kohl et al., 2004) 2015 (2) (Kohl et al.) Strong d (12 GE, 2 EE) Six genes are associated with the disease. Variants in ATF6 have been found in at least 12 families in the literature (Kohl et al., 2004) . >16 genes are associated with HCM. KLF10 variants account for < 1% of cases (Cirino & Ho, 2008) . Eleven genes are associated with the disease. NHP2 variants account for < 1% of cases (Savage, 2009) .
XRCC4
PDZD7
JPH2
Hypertrophic cardiomyopathy (AD)
ORPHA 217569 OMIM #613873
1:500 (Cirino & Ho, 2008) 2007 (10) (Landstrom et al.) Moderate f (4.2 GE, 4.5 EE)
>16 genes are associated with HCM. JPH2 variants account for < 1% of cases (Cirino & Ho, 2008) .
AKAP9
Long QT syndrome (AD)
ORPHA 101016 OMIM #611820 1-5:10,000
2007 (10) (Chen et al.) Limited d (0.5 GE, 1.5 EE)
Fifteen genes are associated with LQTS. Variants in AKAP9 account for < 1% of cases (Alders et al., 2003) .
RPS24
Diamond-Blackfan anemia (AD)
ORPHA 124 OMIM #610629
1:100,000-1:200,000 (Clinton & Gazda, 2009) 2006 (11) (Gazda et al.) Definitive d (10.5 GE, 3.5 EE, r/t) ∼2% of cases are attributed to variants in RPS24 (Clinton & Gazda, 2009) .
ORPHA 154 OMIM N/A 1:250 (Hershberger & Morales, 2007) 2005 (12) (Taylor et al.) Refuted d Only 1 proband with a TMPO variant reported in the literature, which was later refuted (Strande et al., 2017) .
ORPHA 217569 OMIM #607487
1:500 (Cirino & Ho, 2008) 2004 (13) (Hayashi et al.) Limited f (0.2 GE, 1 EE)
>16 genes are associated with HCM. TCAP variants account for < 1% of cases (Cirino & Ho, 2008) . (Rahman & Thorburn, 2015) 2003 (15) (Antonicka, et al.) Strong f,h (8 GE, 5 EE)
MYO1A
<5% of complex IV-deficient Leigh syndrome is caused by variants in COX15 (Rahman & Thorburn, 2015) .
USH1C
Usher syndrome type 1C (AR)
ORPHA 231169 OMIM #276904 1-9:100,000
2000 (17) (Verpy et al.) Definitive g (12 GE, 6 EE, r/t) Six genes are associated with the disease. 1-15% of cases are attributed to variants in USH1C (Lentz & Keats, 1999) . 1:500 (Cirino & Ho, 2008) 1994 (23) (Thierfelder et al.) Definitive f (12 GE, 6 EE, r/t) ∼2% of HCM cases are caused by variants in TPM1 (Cirino & Ho, 2008) .
SMAD4
GAA
Pompe disease (AR) ORPHA 365 OMIM #232300
1:14,000-1:100,000 (Leslie & Bailey, 2007) 1991 (26) (Zhong et al. 2011) Definitive c (12 GE, 6 EE, r/t)
GAA is the only gene associated with Pompe disease (Leslie & Bailey, 2007 at one year-increments. A "Limited" classification scored up to 6 total points, a "Moderate" classification scored 7-11 total points, a "Strong" classification scored 12-18 total points, and a "Definitive" classification scored 12-18 points with replication over time (> 3 years).
A "Disputed/Refuted" classification represents those gene-disease associations in which conflicting evidence for the role of the gene in the disease was reported.
Population databases-the Exome Aggregation Consortium (ExAC; exac.broadinstitute.org) and the Genome Aggregation Consortium Genetics, volume 93 (issues 1 and 2) were selected for analysis (Table 2) .
Curations were simulated at one-year increments from 2013 to 2016.
Statistical analysis was performed using an unpaired t-test (GraphPad). All current gene-disease validity summaries can be found on the ClinGen website (www.clinicalgenome.org) by searching the HGNC gene symbol provided in Tables 1 and 2 .
RESULTS
In order to observe any trends in clinical validity classifications over time, a diverse selection of 22 curated gene-disease associations (Table   1 ) were evaluated at one-year intervals using the ClinGen gene curation framework, starting with the year of the first publication to assert disease-causing variants in the gene of interest ( Figure 1 ). Of the 22 gene-disease associations, six are currently classified as "Limited,"
three are "Moderate," three are "Strong," seven are "Definitive" and three are "Refuted." The gene-disease associations were chosen to encompass a range of clinical domains, inheritance patterns, pathologies, molecular mechanisms, and time at first assertion and were selected from available curations that had been performed by ClinGen Gene Curation Expert Panels. On average, over the entire lifetime of a gene-disease association (from first assertion to the latest assessment for this study, 2017), gene-disease pairs tended to spend a higher percentage of time at the "Limited" classification (71.4 ± 34.9%) compared to "Moderate" (41.5 ± 34.6%) (Figure 2A ). Given that the point range for the "Moderate" classification is four points (7-11), compared to "Limited" and "Strong/Definitive" that are 5.9 (0.1-6) and six points (12-18), respectively, it is logical that gene-disease associations would spend the least amount of time in the "Moderate" classification. Consistent with this observation, we found that 71% of gene-disease associations that spent more than a year at the "Moderate" classification progressed to "Strong" (1/7) or "Definitive" (4/7) by 2017. Of note, JPH2: hypertrophic cardiomyopathy was excluded from this analysis as it had only reached the "Moderate" classification within the last year of the curation time frame, and thus was not subject to the analysis. Only 2/7 gene-disease associations remain at "Moderate" (Figure 2B ), suggesting that these associations may spend a fractional amount of time at "Moderate" before advancing to a new classification. Furthermore, it should be noted that we did not encounter a gene-disease association that achieved a "Moderate" classification that then moved to a "Disputed" or "Refuted" classification, further supporting the suggestion that once a gene-disease association meets a classification of "Moderate" it will most likely advance to "Strong" or "Definitive."
TA B L E 2 List of novel gene-disease associations from volume 93 (Issues 1 and 2) of the
In assessing gene-disease associations with a "Limited" classification, we found that out of the ten genes that spent at least three or more years at "Limited," 50% of them currently remain at "Limited." Only 2/10 progressed to a higher classification: one each to "Moderate" and "Definitive," while 3/10 became "Disputed/Refuted" ( Figure 2C ). This observation is consistent with the finding that genedisease associations spend more time at the "Limited" classification, compared to "Moderate" and "Strong" (Figure 2A ). This trend was even more significant when we looked at gene-disease associations that spent at least five or more years at "Limited": only 1/8 progressed to a higher classification, while 4/8 stayed at "Limited" and 3/8 became "Disputed/Refuted" ( Figure 2D ). It is interesting to note that genedisease associations that began as "Limited" and were reclassified as "Disputed/Refuted" only reached a maximum of two points in genetic and experimental evidence before conflicting evidence was Diamond-Blackfan anemia, and COX15: Leigh syndrome) initially scored more than two points at the time of the first assertion. These findings suggest that gene-disease associations at the low end of the "Limited" point range (< 2 points) are more likely to remain "Limited"
or become "Disputed/Refuted" than gene-disease associations that initially scored in mid to upper "Limited" point range (2-6 points).
Disputed/refuted gene-disease associations
Three out of 22 genes analyzed spent between 9 and 20 years at (Table 1) . KLHL24: epidermal bullosa simplex and SERPINB8: exfoliative ichthyosis were excluded from this analysis as they have only been classified at one time point and have not had time to change classification. Mean percentages of time spent at each classification are as follows: 71.4 ± 34.9% at "Limited," 41.5 ± 34.6% at "Moderate," 33.4 ± 34.9% at "Strong," 64.0 ± 26.2% at "Definitive," and 19.8 ± 6.2% at "Disputed/Refuted." (b) Current clinical validity classifications of genes that spent more than one year at "Moderate." JPH2: hypertrophic cardiomyopathy was excluded from this analysis as it has only been classified at one time point and has not had time to change classification. Two out of seven of those gene-disease associations remain at "Moderate," 1/7 progressed to "Strong," and 4/7 progressed to "Definitive." (c) Current clinical validity classifications of genes that spent at least three years at "Limited." Five out of ten gene-disease associations remain at "Limited," 1/10 progressed to "Moderate," 1/10 progressed to "Definitive," and 3/10 are now "Disputed/Refuted." 
Impact of new sequencing technologies on clinical validity classifications
In recent years, advancements in sequencing technologies, such as next-generation sequencing (NGS) and whole exome sequencing nemaline myopathy reached the point range for a "Strong" classification in 2013, it was downgraded to "Moderate" as a "Strong" classification requires two or more independent studies to reach this classification per the ClinGen gene curation framework. In 2016, both KLHL40: nemaline myopathy and PIK3R1: SHORT syndromes were upgraded to "Definitive" due to replication over time (indicated by r/t) three independent studies implicating the gene's role in disease were published in the same issue (Chudasama et al., 2013; Dyment et al., 2013; Thauvin-Robinet et al., 2013) . Both KLHL40: nemaline myopathy and PIK3R1: SHORT syndrome reached a final classification of "Definitive" in 2016 due to replication over time.
In order to further investigate how the next generation of sequencing technologies may have impacted the clinical validity classification over time, we focused our analysis to the ten "Definitive" gene-disease associations (Tables 1 and 2 , Figures 1 and 3) . The ten gene-disease pairs were divided into two groups: those that were discovered using traditional methods (linkage analysis, direct sequencing) prior to 2010
(GAA: Pompe disease, TPM1: hypertrophic cardiomyopathy, SMAD4:
juvenile polyposis syndrome, USH1C: Usher syndrome type 1C, RPS24:
Diamond-Blackfan anemia, and PDZD7: sensorineural hearing loss) and those that were discovered using modern genomic technology (WES) after 2010 (ABCC9: Cantu syndrome, KLHL40: nemaline myopathy, and PIK3R1: SHORT syndrome).
There was no significant difference in the average amount of time it took for the gene-disease associations to reach "Definitive" between the pre-2010, traditional methods group (4.33 ± 1.37 years)
versus the post-2010, WES group (3.0 ± 0 years, P = 0.1465) ( Figure 4A ). However, there was a significant increase in the average number of probands curated per paper for the post-2010, WES group (1.98 ± 0.55 vs. 8.5 ± 3.29, P = 0.0015) ( Figure 4B ), suggesting that next-generation sequencing technologies may allow researchers to analyze a greater number of cases, while those gene-disease associations that were discovered using traditional methods relied on more papers to reach "Definitive" status. In fact, this trend was observed when we looked at the number of papers curated for both groups ( Figure 4C ), though it did not reach significance, which is likely due to a small sample size. For the pre-2010 group, an average of 9.7 ± 3.7 papers were curated to reach "Definitive" status versus 5.0 ± 1.0 papers curated for the post-2010 group (P = 0.0742).
DISCUSSION
As the number of completed gene curations continues to grow, ClinGen gene curation groups will need to determine how often gene-disease associations will be reevaluated in order to stay up-todate with new information as it becomes available in the literature.
Analysis of the 30 gene-disease associations discussed here can begin to provide insight into how the clinical validity classification changes over time. This analysis is not only relevant to ClinGen curation activities, but can also be applied by any groups offering diagnostic testing to determine how often genes on panels are assessed. A systematic approach for reanalysis of genes on diagnostic testing panels will help to ensure the most accurate results are reported.
The first thing to consider when determining how often to reevaluate a gene-disease association is the initial clinical validity classification. In effect, the "Limited" classification was intended to represent a relatively weak single publication with few cases and little supporting functional evidence, while the "Moderate" classification was intended to represent a stronger initial publication providing more cases and ample functional evidence supporting the gene's role in the disease. A "Strong" classification implies additional independent corroboration of an initial gene-disease association, increasing both the case-level and gene-level evidence.
There are several reasons why gene-disease associations may stay at "Limited" for a longer period of time. First, the disease may be rare, in which case there are very few probands reported in the literature.
It is important to note, however, that with the ClinGen framework, it is possible for even rare gene-disease associations to reach a "Strong"
or "Definitive" classification based on the strength of available variant evidence and supporting experimental evidence. Secondly, the gene of interest may be only one of many genes known to cause the same disease and therefore variants in that gene only account for a small number of cases. For example, TCAP, AKAP9, NHP2, and KLF10 account for fewer than 1% of cases of their respective diseases, which are caused by variants in more than ten genes each (see notes on Table 1 ). Finally, a gene-disease association may spend a greater time at "Limited" due to disparities in research and funding for different clinical domains.
For these reasons, a gene-disease association may remain at "Limited" for several years, but with the availability of technologies such as WES, and resources such as GeneMatcher (www.genematcher.org) and GenomeConnect (www.genomeconnect.org) that allow clinicians and researchers who are interested in the same gene to connect, it may eventually progress to a new classification with time.
When determining how often to reevaluate a "Limited" genedisease association, it is appropriate to consider the length of time (Tables 1 and 2 ). Conversely, "Limited" gene-disease associations, such as AKAP9: long QT syndrome and TCAP: hypertrophic cardiomyopathy, that have fewer than two points and have remained "Limited" for more than 10 years (Table 1, Figure 1 ) should be reevaluated less frequently, and importantly they should be monitored for newly published data that could dispute or refute the gene-disease association.
Not surprisingly, gene-disease associations tend to spend less time in the "Moderate" category compared to "Limited." This is likely due to the small point range for this category compared to "Limited" and "Strong/Definitive" and the fact that any corroborating publications would be likely to push the supporting evidence into the "Strong" category. Similar to gene-disease associations at the high end of the point range for "Limited," curation groups may want to reevaluate "Moderate" associations more frequently, and automated systems for alerting curation groups to new publications about the gene or disease would help to keep categorizations up to date. Gene-disease associations also spend very little time at "Strong" due to the fact that they can reach "Definitive" once the association has been upheld for at least three years (Strande et al., 2017) . "Strong" gene-disease associations would therefore only need to be reevaluated once they reach the 3-year mark for replication over time.
Given the availability of more advanced genomic sequencing technologies, large population databases, and resources like GeneMatcher In summary, the results from this retrospective study provide several key points to consider when determining how often to reevaluate a gene-disease association. First, "Limited" classifications should be considered carefully. Gene-disease associations that have been at the low end of the "Limited" point range (e.g. < 2 points) for an extended period of time (e.g. > 5 years) and have not been disputed/refuted with the release of ExAC or gnomAD, may not need to be evaluated as frequently as those at the higher end of the "Limited" point range and those that have been discovered more recently. Low "Limited" genedisease associations may only need to be evaluated every three to five years, while high "Limited" gene-disease associations every one to two years. Eventually, consensus groups may need to reassess the original evidence and determine whether failure to replicate the initial finding constitutes a justification for disputing the gene-disease association.
"Moderate" gene-disease associations should be reevaluated more frequently, possibly every one to two years, given the small point range for the category. Finally, "Strong" gene-disease associations should be re-evaluated at the three-year mark to reflect replication over time, allowing the association to reach the "Definitive" classification. These recommendations are based on our initial review. However, reanalysis and adjustment of these time points may be required in the future once more gene-disease associations have been analyzed.
Overall, this study has provided insight into the process of biocuration and has given key consideration points in determining the most effective reevaluation process for gene-disease association classifications.
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